Lipid Nanotechnology

Lipid nanoparticles (LNPs) are lipid-based nanoparticles. They are a novel pharmaceutical formulation and a novel pharmaceutical drug delivery method. LNPs were initially approved as a medication delivery vehicle in 2018 for the siRNA drug Onpattro. Some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle, making LNPs more well-known in late 2020. A solid lipid nanoparticle is usually spherical, with a diameter ranging from 10 to 1000 nanometers. A solid lipid core matrix in solid lipid nanoparticles can solubilize lipophilic compounds. Surfactants help to keep the lipid core stable.

Gene Therapy

Cancer Therapy

Diagnostics Delivery

Protein and Peptide Delivery

Antioxidant and Vitamin Delivery

Overcoming the Blood-Brain Barrier

Market Analysis:  The global lipids market was valued at USD 6.5 billion in 2017 and is expected to grow at a 9.4% CAGR from 2017 to 2022, hitting $11.2 billion in 2022.